Notch1 Protein is a protein involved in key cellular signaling pathways relevant to neurodegenerative diseases. This page provides comprehensive information about its structure, normal biological function, and role in disease pathogenesis.
Notch1 Protein participates in critical cellular processes that, when dysregulated, contribute to neurodegeneration. Understanding this protein's function is essential for developing therapeutic interventions for Alzheimer's disease, Parkinson's disease, and related conditions.
| Notch1 Protein | |
|---|---|
| Protein Name | Notch1 |
| Gene | [NOTCH1](/genes/notch1) |
| UniProt ID | P46531 |
| PDB Structure | 1TOZ, 5M2X, 6A0O |
| Molecular Weight | 272 kDa (full length), 110 kDa (transmembrane fragment) |
| Subcellular Localization | Cell membrane, Nucleus (after cleavage) |
| Protein Family | Notch family (type I transmembrane receptor) |
Notch1 is a type I transmembrane receptor consisting of an extracellular domain (NECD), a transmembrane domain, and an intracellular domain (NICD). The extracellular domain contains 36 EGF-like repeats and 3 LIN-12/Notch repeats (LNR). The transmembrane domain anchors the protein in the plasma membrane. Upon ligand binding, Notch1 undergoes two proteolytic cleavages: first by ADAM proteases (S1 cleavage), then by γ-secretase (S2 cleavage), releasing the NICD that translocates to the nucleus.
Notch1 is a transmembrane receptor that mediates cell-cell communication through the Notch signaling pathway. Upon binding of ligands (Delta-like or Jagged family), Notch1 undergoes proteolytic cleavage, releasing the intracellular domain (NICD) that translocates to the nucleus. In neurons, Notch1 regulates neurogenesis, synaptic plasticity, and neuronal survival. It interacts with the transcriptional regulators CSL (CBF1/RBP-Jκ/Su(H)/LAG-1) and Mastermind to activate target genes including HES (Hairy and Enhancer of Split) and HEY (Hairy/Enhancer-of-Split related with YRPW motif) families.
NOTCH1 mutations cause Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL), leading to stroke and vascular dementia. In Alzheimer's disease, Notch1 interacts with amyloid precursor protein processing and Aβ toxicity. Notch1 signaling is altered in AD brains and may contribute to synaptic dysfunction and neuroinflammation.
Notch1 signaling modulators are being developed for cancer and potentially for neurodegenerative diseases. Gamma-secretase inhibitors block Notch1 activation but have problematic side effects due to broad γ-secretase inhibition. More selective Notch1 inhibitors and monoclonal antibodies targeting the Notch1 ligand-binding domain are in development. For CADASIL, no disease-modifying therapy exists, but Notch1-targeted approaches are being explored.